Targeting the microtubular network as a new antimyeloma strategy

Molecular Cancer Therapeutics

Volumn 10, Issue 10, 2011, Pages 1886-1896

  Feng, Rentian ^a   Li, Shirong ^a   Lu, Caisheng ^a   Andreas, Carrie ^a   Stolz, Donna B ^b   Mapara, Markus Y ^a   Lentzsch, Suzanne ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; BIM PROTEIN; DEXAMETHASONE; FENBENDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE 12; NOCODAZOLE; PROTEIN BCL 2; PROTEIN MCL 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SYNAPTOPHYSIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CANCER SURVIVAL; CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CONTROL STRATEGY; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; MITOCHONDRIAL TARGETING SIGNAL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROMETAPHASE; PROPHASE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; STROMA CELL; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MAP KINASE KINASE 4; MICE; MICROTUBULES; MULTIPLE MYELOMA; NOCODAZOLE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOM ALLOCATION; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053976235     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0234     Document Type: Article

References (43)

1. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centro-some targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203. (Pubitemid 36565761)
2. Ayensu WK, Tchounwou PB. Microarray analysis of mercury-induced changes in gene expression in human liver carcinoma (HepG2) cells: importance in immune responses. Int J Environ Res Public Health 2006;3:141-73. (Pubitemid 350002698)
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65. (Pubitemid 38525281)
4. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998;273:4928-36. (Pubitemid 28108645)
5. Deng X, Gao F, Flagg T, Anderson J, May WS. Bcl20s flexible loop domain regulates p53 binding and survival. Mol Cell Biol 2006;26:4421-34. (Pubitemid 43877564)
6. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A 1995;92:4507-11.
7. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, et al. Bcl-2 undergoes phosphorylation by c-Jun Nterminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 1997;272:25238-42. (Pubitemid 27415712)
8. Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H, et al. Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation. J Biol Chem 2000;275:21661-7. (Pubitemid 30481874)
9. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999;19:8469-78. (Pubitemid 30414041)
10. Katiyar SK, Gordon VR, McLaughlin GL, Edlind TD. Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence. Antimicrob Agents Chemother 1994;38:2086-90. (Pubitemid 24278805)
11. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 2002;8:2963-9. (Pubitemid 35025745)
12. Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 2006;12:1928-35.
13. Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010;115:4824-33.
14. Feng R, Rios JA, Onishi T, Lokshin A, Gorelik E, Lentzsch S. Cellbased and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res 2010;34:917-24.
15. Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY, et al. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-{kappa}B activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 2007;109:2130-8. (Pubitemid 46348215)
16. Pal R, Janz M, Galson DL, Gries M, Li S, Johrens K, et al. C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood 2009;114:3890-8.
17. Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther 2008;7:1494-505.
18. Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD,et al. Immunomodulatory derivatives induce PU.1down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010;115:605-14.
19. Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, et al. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002;62:2300-5. (Pubitemid 34411708)
20. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiplemyeloma. J Clin Oncol 2005;23:6345-50. (Pubitemid 46218845)
21. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33. (Pubitemid 27038278)
22. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
23. Monaghan K, Khong T, Smith G, Spencer A. CYT997 causes apoptosis in human multiple myeloma. Invest New Drugs 2011;29:232-8.
24. Bozko P, Sabisz M, Larsen AK, Skladanowski A. Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications. Mol Cancer Ther 2005;4:2016-25. (Pubitemid 43056985)
25. Ho YS, Duh JS, Jeng JH, Wang YJ, Liang YC, Lin CH, et al. Griseofulvin potentiates antitumorigenesis effects of nocodazole through induction of apoptosis and G2/M cell cycle arrest in human colorectal cancer cells. Int J Cancer 2001;91:393-401. (Pubitemid 32049635)
26. Woodtli W, Bircher J, Witassek F, Eckert J, Wuthrich B, Ammann RW. Effect of plasma mebendazole concentrations in the treatment of human echinococcosis. Amer J Trop Med Hyg 1985;34:754-60. (Pubitemid 16237022)
27. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007;8:379-93. (Pubitemid 46643240)
28. Bekier ME, Fischbach R, Lee J, Taylor WR. Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Mol Cancer Ther 2009;8:1646-54.
29. Logarinho E, Bousbaa H. Kinetochore-microtubule interactions "in check" by Bub1, Bub3 and BubR1: the dual task of attaching and signalling. Cell Cycle 2008;7:1763-8. (Pubitemid 351988741)
30. Zieve GW, Turnbull D, Mullins JM, McIntosh JR. Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole. Nocodazole accumulated mitotic cells. Exp Cell Res 1980;126:397-405. (Pubitemid 10041174)
31. Chan YW, Ma HT, Wong W, Ho CC, On KF, Poon RY. CDK1 inhibitors antagonize the immediate apoptosis triggered by spindle disruption but promote apoptosis following the subsequent rereplication and abnormal mitosis. Cell Cycle 2008;7:1449-61. (Pubitemid 351872584)
32. Nusse M, Egner HJ. Can nocodazole, an inhibitor of microtubule formation, be used to synchronize mammalian cells? Accumulation of cells in mitosis studied by two parametric flow cytometry usingacridine orange and by DNA distribution analysis. Cell Tissue Kinet 1984;17:13-23. (Pubitemid 14199676)
33. Uetake Y, Sluder G. Prolonged prometaphase blocks daughter cell proliferation despite normal completion of mitosis. Curr Biol 2010;20:1666-71.
34. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002;62:2462-7. (Pubitemid 34462718)
35. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999;3:287-96. (Pubitemid 29290669)
36. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100:194-9. (Pubitemid 35177447)
37. Warr MR, Shore GC. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008;8:138-47. (Pubitemid 351516833)
38. Kaur S, Wang F, Venkatraman M, Arsura M. X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta1 (TGF-beta1) through ubiquitinmediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1). J Biol Chem 2005;280:38599-608. (Pubitemid 43853761)
39. Du LLyle CS, Chambers TC. Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 2005;24:107-17.
40. Bassik MC, Scorrano L, Oakes SA, Pozzan T, Korsmeyer SJ. Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. EMBO J 2004;23:1207-16. (Pubitemid 38436884)
41. Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 2008;6:1308-15.
42. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 1998;58:1609-15. (Pubitemid 28215079)
43. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, et al. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 1998;273:30777-84. (Pubitemid 28545562)